Ptc Therapeutics (PTCT) Cost of Revenue (2017 - 2025)
Historic Cost of Revenue for Ptc Therapeutics (PTCT) over the last 9 years, with Q3 2025 value amounting to $15.8 million.
- Ptc Therapeutics' Cost of Revenue rose 4547.38% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year decrease of 1977.28%. This contributed to the annual value of $57.4 million for FY2024, which is 1235.07% down from last year.
- As of Q3 2025, Ptc Therapeutics' Cost of Revenue stood at $15.8 million, which was up 4547.38% from $11.4 million recorded in Q2 2025.
- In the past 5 years, Ptc Therapeutics' Cost of Revenue ranged from a high of $29.1 million in Q4 2023 and a low of $6.5 million during Q3 2021
- In the last 5 years, Ptc Therapeutics' Cost of Revenue had a median value of $11.4 million in 2025 and averaged $12.6 million.
- As far as peak fluctuations go, Ptc Therapeutics' Cost of Revenue soared by 16730.93% in 2023, and later tumbled by 4407.93% in 2024.
- Ptc Therapeutics' Cost of Revenue (Quarter) stood at $9.3 million in 2021, then rose by 16.79% to $10.9 million in 2022, then soared by 167.31% to $29.1 million in 2023, then plummeted by 44.08% to $16.3 million in 2024, then dropped by 3.08% to $15.8 million in 2025.
- Its last three reported values are $15.8 million in Q3 2025, $11.4 million for Q2 2025, and $12.9 million during Q1 2025.